Is Routine Central Neck Dissection Necessary for the Treatment of Papillary Thyroid Microcarcinoma?

다국어 초록 (Multilingual Abstract)

Objectives. It remains unclear as to whether routine central neck dissection (CND) is necessary when performing surgery
to treat patients with papillary thyroid microcarcinoma (PTMC). To determine the necessity for routine CND in
PTMC patients, we reviewed the clinicopathologic and laboratory data of the patients of PTMC.
Methods. Between September 2001 and July 2005, 101 patients with PTMC and clinical N0 disease were retrospectively
reviewed. The study cohort was devided into groups: the total thyroidectomy plus CND group (the CND group,
N=48) and the total thyroidectomy without CND group (the no CND group, N=53). The serum stimulated thyroglobulin
(Tg) levels were measured after surgery and prior to radioactive iodine ablation therapy (RAI) and at
6-12 months after RAI. Pathology, the Tg levels and recurrence data were compared between the 2 groups.
Results. Central nodal metastases were found in 18 of the 48 CND patients (37.5%). The incidence of Tg levels >5 ng/mL
at RAI was higher in the no CND patients and in the 18 node-positive CND patients compared with the 30 nodenegative
CND patients (22-24% vs. 3%, respectively, P=0.020-0.058). The difference when performing a similar
comparison using a >2 ng/mL Tg threshold level showed no significance (10-11% vs. 4%, respectively, P>0.1).
Two of the no CND patients and one node-positive CND patient had recurrences in the thyroid bed or lateral neck
during a mean follow-up of 24 months.
Conclusion. The data showed that occult metastasis to the central neck is common in PTMC patients. A CND provides
pathologic information about the nodal metastases, and it potentially provides guidance for planning the postoperative
RAI. However, the long-term benefit of CND on recurrence and survival remains somewhat questionable.

다국어 초록 (Multilingual Abstract)

Objectives. It remains unclear as to whether routine central neck dissection (CND) is necessary when performing surgery
to treat patients with papillary thyroid microcarcinoma (PTMC). To determine the necessity for routine CND in
PTMC patients, we reviewed the clinicopathologic and laboratory data of the patients of PTMC.
Methods. Between September 2001 and July 2005, 101 patients with PTMC and clinical N0 disease were retrospectively
reviewed. The study cohort was devided into groups: the total thyroidectomy plus CND group (the CND group,
N=48) and the total thyroidectomy without CND group (the no CND group, N=53). The serum stimulated thyroglobulin
(Tg) levels were measured after surgery and prior to radioactive iodine ablation therapy (RAI) and at
6-12 months after RAI. Pathology, the Tg levels and recurrence data were compared between the 2 groups.
Results. Central nodal metastases were found in 18 of the 48 CND patients (37.5%). The incidence of Tg levels >5 ng/mL
at RAI was higher in the no CND patients and in the 18 node-positive CND patients compared with the 30 nodenegative
CND patients (22-24% vs. 3%, respectively, P=0.020-0.058). The difference when performing a similar
comparison using a >2 ng/mL Tg threshold level showed no significance (10-11% vs. 4%, respectively, P>0.1).
Two of the no CND patients and one node-positive CND patient had recurrences in the thyroid bed or lateral neck
during a mean follow-up of 24 months.
Conclusion. The data showed that occult metastasis to the central neck is common in PTMC patients. A CND provides
pathologic information about the nodal metastases, and it potentially provides guidance for planning the postoperative
RAI. However, the long-term benefit of CND on recurrence and survival remains somewhat questionable.

참고문헌 (Reference)

• 1 Tisell LE, 20 (20): 854-859, 1996
• 2 Yokozawa T, "Thyroid cancer detected by ultrasound-guided fine-needle aspiration biopsy" 20 (20): 848-853, 1996
• 3 Hedinger C, "The WHO histological classification of thyroid tumors: a commentary on the second edition" 63 (63): 908-911, 1989
• 4 Sugitani I, "Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors" 46 (46): 209-216, 1999
• 5 Kim TY, "Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma" 90 (90): 1440-1445, 2005
• 6 Wartofsky L, "Schlumberger M, Hay ID. The use of radioactive iodine in patients with papillary and follicular thyroid cancer" 83 (83): 4195-4203, 1998
• 7 Menendez Torre E, "Prognostic value of thyroglobulin serum levels and 131I whole-body scan after initial treatment of low-risk differentiated thyroid cancer" 14 (14): 301-306, 2004
• 8 Baudin E, "Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients" 88 (88): 1107-1111, 2003
• 9 Rodriguez JM, "Papillary thyroid microcarcinoma: clinical study and prognosis" 163 (163): 255-259, 1997
• 10 Hay ID, "Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period" 112 (112): 1139-1146, 1992
• 11 Hay ID, "Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and longterm outcome in 2444 consecutively treated patients" 26 (26): 879-885, 2002
• 12 Bramley MD, "Papillary microcarcinoma of the thyroid gland" 83 (83): 1674-1683, 1996
• 13 Harach HR, "Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study" 56 (56): 531-538, 1985
• 14 Yamamoto Y, "Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases" 65 (65): 1173-1179, 1990
• 15 Strate SM, "Occult papillary carcinoma of the thyroid with distant metastases" 54 (54): 1093-1100, 1984
• 16 Harach HR, "Occult papillary carcinoma of the thyroid appearing as lung metastasis" 108 (108): 529-530, 1984
• 17 Pereira JA, "Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma" 138 (138): 1095-1100, 2005
• 18 Henry JF, "Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma" 383 (383): 167-169, 1998
• 19 Wada N, "Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection" 237 (237): 399-407, 2003
• 20 Mazzaferri EL, "Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer" 97 (97): 418-428, 1994
• 21 Williams ED, "Guest editorial: two proposals regarding the terminology of thyroid tumors" 8 (8): 181-183, 2000
• 22 Ito Y, "Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid" 30 (30): 91-99, 2006
• 23 Sawka AM, "Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for welldifferentiated thyroid cancer" 89 (89): 3668-3676, 2004
• 24 Mazzaferri EL, "Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer" 86 (86): 1447-1463, 2001